Intended for healthcare professionals

Research Fast Facts

Future-case control crossover analysis for adjusting bias in case crossover studies

BMJ 2023; 382 doi: https://doi.org/10.1136/bmj.p2136 (Published 27 September 2023) Cite this as: BMJ 2023;382:p2136

Linked research

Association between recently raised anticholinergic burden and risk of acute cardiovascular events

Linked editorial

Anticholinergic medicines linked to cardiovascular events in older adults

  1. Wei-Ching Huang, masters student,
  2. Edward Chia-Cheng Lai, professor
  1. School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, 701 Tainan, Taiwan
  1. Correspondence to: EC-C Lai edward_lai{at}mail.ncku.edu.tw

This article outlines the issues of exposure time trends in the case crossover design and the implementation of the case-case-time-control design, a control crossover analysis using “future cases” to adjust the exposure time trends. The future-case control crossover analysis minimises the influence of constant time confounders, as well as the protopathic bias arising from exposure time trends.

Overview of case crossover design

The case crossover study is a self-controlled, outcome anchored design to assess the association between transient exposures and acute outcomes.1 The design compares the likelihood of exposure during a hazard window (a predefined time period when exposure might cause the event) and a reference window (a predefined time period before the hazard window when exposure is less likely to cause the outcomes) in order to infer possible causality between exposure and outcome. A case crossover study usually includes a washout window between the aforementioned two windows to ensure that any effects from a previous drug exposure have been eliminated. The case crossover study has become one of the most efficient tools for drug safety assessment because it only requires groups of people who have experienced adverse events (case only design); this eliminates the need for external control populations, because patients serve as their own controls. This within person comparison also reduces the impact of time invariant confounders such as sex or family history.2

The need for control crossover analysis

Exposure time trends are inherent limitations in case crossover studies because these trends can introduce differentials in the likelihood of exposure between the hazard and reference windows that are unrelated to the outcomes.3 Two types of time trends need to be considered. Time trends at the population level often relates to drug availability or preferences in drug use; for example, the introduction of a new drug might increase its use across the entire population. Time trends at the individual level usually occur in specific patient conditions. For example, patients who experience events might start or stop using drugs for early symptoms of events before receiving a confirmed diagnosis, which can result in higher (or lower) exposure rates during the hazard windows than the reference windows. Incorporating a control crossover analysis into a case crossover study is therefore suggested to reduce such biases arising from exposure time trends.

Control crossover analysis with “future case” patients

Case-time-control analysis and case-case-time-control analysis were developed to adjust for exposure time trends in case crossover studies.45 These methods include a control group for a control crossover analysis conducted analogously to the case crossover analysis, for the purpose of assessing the exposure time trends. The main difference between the two control crossover designs is the source of the controls; the case-time-control design includes non-case external controls, whereas the case-case-time-control design uses “future cases.” Specifically, the future cases are selected from the original cases (or “current cases”) using risk set sampling, such as matching by age, sex, or other characteristics, to make the risk for events during the person time of the two groups similar. In this design, the control crossover analysis basically shifts both the hazard and the reference windows backwards by a specified time period from the original event date. Because the index date transitions from the original event date to an earlier one, it appears as if the patients are to experience the events subsequently, in the near future, and they are therefore referred to as “future cases.” Because both the current cases and the future cases experience the outcome of interest, the exposure time trends at individual level are assumed to be similar. Population level time trends can also be minimised, as we usually consider matching the calendar time when sampling control populations of future cases. Figure 1 schematically presents case crossover analysis, different types of exposure time trend bias, and how control crossover analyses minimise exposure time trend effects.

Fig 1
Fig 1

Schematic presentation of different case crossover designs and the exposure time trend bias

Specifically, the method assumes that the odds ratio observed from the case crossover analysis is influenced by both the causal effect and the time trend effect (ie, ORcase=ORcausal×ORtime trend), and that the odds ratio observed from the future-case control crossover analysis estimates the time trend effect (ORcontrol=ORtime trend). The causal effect odds ratio can then be derived by dividing the odds ratios from the case crossover analysis and the control crossover analysis (ie, ORcausal=ORcase÷ORtime trend=ORcase÷ORcontrol). Given that both current and future cases experience the events, we can assume that they share a comparable individual level time trend of exposure. Moreover, this approach can also mitigate population level trend bias, given that the index date for a future case is the same as the date of the matched current case, sharing identical calendar time spans.

Control crossover analysis with future case controls could be an effective approach to resolve protopathic bias, which derives from exposure time trends at the individual level. For example, Huang and colleagues assessed the association between recently raised anticholinergic burden and cardiovascular events.6 Because a clinician might prescribe drugs (such as anti-vertigo drugs for dizziness) for the symptoms of cardiovascular events before a confirmed diagnosis, the use of the drugs during hazard windows might appear elevated, compared with the reference windows. This individual level time trend could generate reverse causality between drug use and outcomes (ie, protopathic bias). Control crossover analysis of future cases enables us to estimate the time trend effect and subsequently derive adjusted odds ratios that take the time trend effect into account.

Unlike case-time-control analysis using non-case external controls, an advantage of using future cases for control crossover analysis is that the controls are sampled from the original cases. This eliminates concerns about availability of data for the controls, or about avoiding selection bias when controls do not accurately reflect the target population. The major limitation of this approach is that there are no standard criteria for an appropriate time gap between the event dates of current and future cases. Sensitivity analyses with various time intervals may be considered to examine the assumptions.

Conclusion

The case crossover study is a self-controlled design to assess the association between transient exposures and acute outcomes. By using within person comparisons, it minimises the influence of constant time confounders. However, biases from exposure time trends, whether at the individual or population level, are inherent limitations in case crossover studies. To reduce these biases, integrating a future-case control crossover analysis into a case crossover study could be considered.

Footnotes

  • Funding and competing interests available in the linked paper on bmj.com.

  • Provenance and peer review: Commissioned; not externally peer reviewed.

References